These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
129 related articles for article (PubMed ID: 29970549)
1. Neoadjuvant Radiotherapy with Capecitabine Plus Bevacizumab for Locally Advanced Lower Rectal Cancer: Results of a Single-institute Phase II Study. Maeda K; Shibutani M; Otani H; Fukuoka T; Iseki Y; Matsutani S; Nagahara H; Inoue T; Tachimori A; Nishii T; Miki Y; Hosono M; Ohira M Anticancer Res; 2018 Jul; 38(7):4193-4197. PubMed ID: 29970549 [TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant Chemotherapy with Capecitabine, Oxaliplatin and Bevacizumab Followed by Concomitant Chemoradiation and Surgical Resection in Locally Advanced Rectal Cancer with High Risk of Recurrence - A Phase II Study. Eisterer W; Piringer G; DE Vries A; Öfner D; Greil R; Tschmelitsch J; Samonigg H; Sölkner L; Gnant M; Thaler J; Anticancer Res; 2017 May; 37(5):2683-2691. PubMed ID: 28476845 [TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant oxaliplatin and capecitabine combined with bevacizumab plus radiotherapy for locally advanced rectal cancer: results of a single-institute phase II study. Yu X; Wang QX; Xiao WW; Chang H; Zeng ZF; Lu ZH; Wu XJ; Chen G; Pan ZZ; Wan DS; Ding PR; Gao YH Cancer Commun (Lond); 2018 May; 38(1):24. PubMed ID: 29784042 [TBL] [Abstract][Full Text] [Related]
4. Total neoadjuvant approach with FOLFOXIRI plus bevacizumab followed by chemoradiotherapy plus bevacizumab in locally advanced rectal cancer: the TRUST trial. Masi G; Vivaldi C; Fornaro L; Lonardi S; Buccianti P; Sainato A; Marcucci L; Martignetti A; Luca Urso ED; Castagna M; Fontanini G; Bergamo F; Musettini G; Urbani L; Sensi E; Balestri R; Montrone S; Pasqualetti F; Cremolini C; Di Paolo A; Zagonel V; Falcone A Eur J Cancer; 2019 Mar; 110():32-41. PubMed ID: 30739838 [TBL] [Abstract][Full Text] [Related]
5. A randomized phase II study of capecitabine-based chemoradiation with or without bevacizumab in resectable locally advanced rectal cancer: clinical and biological features. Salazar R; Capdevila J; Laquente B; Manzano JL; Pericay C; Villacampa MM; López C; Losa F; Safont MJ; Gómez A; Alonso V; Escudero P; Gallego J; Sastre J; Grávalos C; Biondo S; Palacios A; Aranda E BMC Cancer; 2015 Feb; 15():60. PubMed ID: 25886378 [TBL] [Abstract][Full Text] [Related]
6. Phase II study of preoperative bevacizumab, capecitabine and radiotherapy for resectable locally-advanced rectal cancer. García M; Martinez-Villacampa M; Santos C; Navarro V; Teule A; Losa F; Pisa A; Cambray M; Soler G; Lema L; Kreisler E; Figueras A; Juan XS; Viñals F; Biondo S; Salazar R BMC Cancer; 2015 Feb; 15():59. PubMed ID: 25886275 [TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant oxaliplatin and capecitabine and bevacizumab without radiotherapy for poor-risk rectal cancer: N-SOG 03 Phase II trial. Uehara K; Hiramatsu K; Maeda A; Sakamoto E; Inoue M; Kobayashi S; Tojima Y; Yoshioka Y; Nakayama G; Yatsuya H; Ohmiya N; Goto H; Nagino M Jpn J Clin Oncol; 2013 Oct; 43(10):964-71. PubMed ID: 23935207 [TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant capecitabine, bevacizumab and radiotherapy for locally advanced rectal cancer: results of a single-institute Phase I study. Miki Y; Maeda K; Hosono M; Nagahara H; Hirakawa K; Shimatani Y; Tsutsumi S; Miki Y J Radiat Res; 2014 Nov; 55(6):1171-7. PubMed ID: 25129557 [TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of Two Neoadjuvant Strategies With Bevacizumab in MRI-Defined Locally Advanced T3 Resectable Rectal Cancer: Final Results of a Randomized, Noncomparative Phase 2 INOVA Study. Borg C; Mantion G; Boudghène F; Mornex F; Ghiringhelli F; Adenis A; Azria D; Balosso J; Ben Abdelghani M; Bachet JB; Vendrely V; François Y; Conroy T; Rio E; Roullet B; Spaëth D; Quero L; Lakkis Z; Coudert M; Ionescu-Goga M; Tanang A; André T Clin Colorectal Cancer; 2019 Sep; 18(3):200-208.e1. PubMed ID: 31311761 [TBL] [Abstract][Full Text] [Related]
10. Influence of concurrent capecitabine based chemoradiotherapy with bevacizumab on the survival rate, late toxicity and health-related quality of life in locally advanced rectal cancer: a prospective phase II CRAB trial. Velenik V; Zadnik V; Omejc M; Grosek J; Tuta M Radiol Oncol; 2020 Aug; 54(4):461-469. PubMed ID: 32738130 [TBL] [Abstract][Full Text] [Related]
11. A phase II study of neoadjuvant chemoradiotherapy with oxaliplatin and capecitabine for rectal cancer. Zhao L; Bai C; Shao Y; Guan M; Jia N; Xiao Y; Qiu H; Zhang F; Yang T; Zhong G; Chen S Cancer Lett; 2011 Nov; 310(2):134-9. PubMed ID: 21782322 [TBL] [Abstract][Full Text] [Related]
12. Phase II trial of neoadjuvant bevacizumab, capecitabine, and radiotherapy for locally advanced rectal cancer. Crane CH; Eng C; Feig BW; Das P; Skibber JM; Chang GJ; Wolff RA; Krishnan S; Hamilton S; Janjan NA; Maru DM; Ellis LM; Rodriguez-Bigas MA Int J Radiat Oncol Biol Phys; 2010 Mar; 76(3):824-30. PubMed ID: 19464823 [TBL] [Abstract][Full Text] [Related]
13. Phase II randomized trial of capecitabine with bevacizumab and external beam radiation therapy as preoperative treatment for patients with resectable locally advanced rectal adenocarcinoma: long term results. Salazar R; Capdevila J; Manzano JL; Pericay C; Martínez-Villacampa M; López C; Losa F; Safont MJ; Gómez-España A; Alonso-Orduña V; Escudero P; Gallego J; García-Paredes B; Palacios A; Biondo S; Grávalos C; Aranda E; BMC Cancer; 2020 Nov; 20(1):1164. PubMed ID: 33246428 [TBL] [Abstract][Full Text] [Related]
14. Preoperative long-course chemoradiation for localized rectal cancer: A retrospective comparison of response and outcome between 5-fluorouracil/leucovorin versus capecitabine. Kunheri B; Gurram B; Madhavan R; Makuny D Indian J Cancer; 2016; 53(4):518-523. PubMed ID: 28485342 [TBL] [Abstract][Full Text] [Related]
15. Preoperative intensity-modulated radiotherapy with a simultaneous integrated boost combined with Capecitabine in locally advanced rectal cancer: short-term results of a multicentric study. Lupattelli M; Matrone F; Gambacorta MA; Osti M; Macchia G; Palazzari E; Nicosia L; Navarria F; Chiloiro G; Valentini V; Aristei C; De Paoli A Radiat Oncol; 2017 Aug; 12(1):139. PubMed ID: 28830475 [TBL] [Abstract][Full Text] [Related]
16. Critical role of bevacizumab scheduling in combination with pre-surgical chemo-radiotherapy in MRI-defined high-risk locally advanced rectal cancer: Results of the BRANCH trial. Avallone A; Pecori B; Bianco F; Aloj L; Tatangelo F; Romano C; Granata V; Marone P; Leone A; Botti G; Petrillo A; Caracò C; Iaffaioli VR; Muto P; Romano G; Comella P; Budillon A; Delrio P Oncotarget; 2015 Oct; 6(30):30394-407. PubMed ID: 26320185 [TBL] [Abstract][Full Text] [Related]
17. A phase II study of cetuximab, capecitabine and radiotherapy in neoadjuvant treatment of patients with locally advanced resectable rectal cancer. Velenik V; Ocvirk J; Oblak I; Anderluh F Eur J Surg Oncol; 2010 Mar; 36(3):244-50. PubMed ID: 20042310 [TBL] [Abstract][Full Text] [Related]
18. Sandwich-like neoadjuvant therapy with bevacizumab for locally advanced rectal cancer: a phase II trial. Xiao J; Chen Z; Li W; Yang Z; Huang Y; Zheng J; Deng Y; Wang L; Ren D; Peng J; Lan P; Wang J Cancer Chemother Pharmacol; 2015 Jul; 76(1):21-7. PubMed ID: 25952796 [TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant sandwich treatment with oxaliplatin and capecitabine administered prior to, concurrently with, and following radiation therapy in locally advanced rectal cancer: a prospective phase 2 trial. Gao YH; Lin JZ; An X; Luo JL; Cai MY; Cai PQ; Kong LH; Liu GC; Tang JH; Chen G; Pan ZZ; Ding PR Int J Radiat Oncol Biol Phys; 2014 Dec; 90(5):1153-60. PubMed ID: 25442042 [TBL] [Abstract][Full Text] [Related]
20. Fluorouracil-based neoadjuvant chemoradiotherapy with or without oxaliplatin for treatment of locally advanced rectal cancer: An updated systematic review and meta-analysis. Yang YJ; Cao L; Li ZW; Zhao L; Wu HF; Yue D; Yang JL; Zhou ZR; Liu SX Oncotarget; 2016 Jul; 7(29):45513-45524. PubMed ID: 27322422 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]